



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	09/806,125	Art Unit:	1642
Filed:	March 28, 2001	Examiner:	S. Rawlings
1 st Inventor:	E. Matsutani	Allowed:	
For:	Agent That Retards Transformation of Hormone-Dependent Cancer to Non-Hormone- Dependent Cancer	Batch:	
Atty. Dkt. No.	2556 US0P	Paper No.:	

Supplemental Information Disclosure Statement

Commissioner for Patents
P.O. Box 1450
Arlington, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, Applicants' request
consideration of the reference listed on the attached form PTO-1449 under §1.97(b).

Should the Examiner believe that a conference with Applicants' attorney would
advance prosecution of this application, the Examiner is respectfully invited to call
Applicants' attorney.


Respectfully submitted,

Dated: September 8, 2004

(847) 383-3391
(847) 383-3372

Elaine M. Ramesh
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Mark Chao, Ph.D., Reg. No. 37,293
Attorney for Applicants
Customer No. 23,115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number 09/806,125

Filing Date March 28, 2001

First Named Inventor E. Matsutani

Art Unit 1642

Examiner Name S. Rawlings

Attorney Docket Number 2556 US0P

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Galbraith, S.M., et al., <u>Androgens and Prostate Cancer: Biology, Pathology and Hormonal Therapy</u> , European Journal of Cancer, 1997, Vol. 33, No. 4., pages 545-554	
		Emons, G., et al., <u>The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers</u> , Human Reproduction Update, 1994, Vol. 9, No. 7, pages 1364-1379	
		Jones, H., et al., <u>New EGF-R Selective Tyrosine Kinase inhibitor reveals variable growth responses in Prostate Carcinoma Cell Lines PC-3 and DU-145</u> , Int. J. Cancer, (1997), 71, pages 1010-1018	
		Fry, D., et al., <u>A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase</u> , Science, 1994, Vol. 265, pages 1093-1095	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.